0001619856-23-000134.txt : 20231212 0001619856-23-000134.hdr.sgml : 20231212 20231212160522 ACCESSION NUMBER: 0001619856-23-000134 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231211 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231212 DATE AS OF CHANGE: 20231212 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Caribou Biosciences, Inc. CENTRAL INDEX KEY: 0001619856 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 453728228 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40631 FILM NUMBER: 231481242 BUSINESS ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 BUSINESS PHONE: 510-982-6030 MAIL ADDRESS: STREET 1: 2929 7TH STREET, SUITE 105 CITY: BERKELEY STATE: CA ZIP: 94710 8-K 1 crbu-20231211.htm 8-K crbu-20231211
FALSE000161985600016198562023-12-112023-12-11

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________
FORM 8-K
________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): December 11, 2023
________________________________________
Caribou Biosciences, Inc.
(Exact name of Registrant as Specified in Its Charter)
________________________________________
Delaware001-4063145-3728228
(State or Other Jurisdiction
of Incorporation)		(Commission File Number)(IRS Employer
Identification No.)
2929 7th Street, Suite 105
Berkeley, California
94710
(Address of Principal Executive Offices)(Zip Code)
Registrant’s Telephone Number, Including Area Code: (510) 982-6030
N/A
(Former Name or Former Address, if Changed Since Last Report)
________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Common Stock, $0.0001 par value per shareCRBUNASDAQ Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Syed Rizvi, M.D., the Chief Medical Officer of Caribou Biosciences, Inc. (the “Company”), will be leaving the Company effective December 31, 2023. Pursuant to Dr. Rizvi’s Officer Employment Agreement with the Company (listed as Exhibit 10.49 to the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022), Dr. Rizvi will become entitled to certain payments and benefits in connection with his termination of employment contingent upon the conditions set forth in the Officer Employment Agreement, including execution and effectiveness of a separation agreement with release of claims in favor of the Company. A search is under way for a new Chief Medical Officer.
Item 7.01 Regulation FD Disclosure.
On December 12, 2023, the Company issued a press release announcing that it had received feedback from the U.S. Food and Drug Administration (the “FDA”) on a phase 3 randomized controlled trial for CB-010, the Company’s genome-edited allogeneic anti-CD19 CAR-T cell therapy in development for patients with second-line relapsed or refractory large B cell lymphoma (“r/r LBCL”). A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and also is incorporated by reference into this Item 7.01.
The information contained in this Item 7.01 and in the accompanying Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing or other document under the Exchange Act or the Securities Act of 1933, as amended (the “Securities Act”), regardless of any general incorporation language in any such filing or document, except as shall be expressly set forth by specific reference in any such filing or document.

Item 8.01 Other Events.
On December 12, 2023, the Company announced that it had received feedback from the FDA following a Type B clinical meeting and recent communications regarding the Company’s genome-edited allogeneic anti-CD19 CAR-T cell therapy, CB-010, in development for patients with second-line r/r LBCL. The FDA provided feedback on a phase 3 randomized controlled trial for CB-010 for patients with r/r LBCL, stating that the Company’s proposed comparator arm of platinum-based immunochemotherapy followed by high dose chemotherapy and autologous stem cell transplantation is acceptable. To the Company’s knowledge, CB-010 is the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting. The Company plans to initiate a phase 3 pivotal trial by year-end 2024.
Forward-Looking Statements
This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not historical facts are forward-looking statements. Forward-looking statements may relate to future events or future performance. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about the Company, its industry, its beliefs and its assumptions. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, without limitation, statements related to the Company’s strategy, plans, and objectives, and expectations regarding its clinical and preclinical development programs, including its expectations relating to the timing of initiating the phase 3 pivotal trial of its CB-010 product candidate. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of the Company’s current and future research and development programs, preclinical studies, and clinical trials; the risk that initial or interim clinical trial data will not ultimately be predictive of the safety and efficacy of the Company’s product candidates or that clinical outcomes may differ as more patient data becomes available; the risk that preclinical study results observed will not be borne out in human patients; the risk that key regulatory input and approvals may not be obtained timely or at all; as well as other risk factors described from time to time in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.


Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
Exhibit No.Description
99.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Caribou Biosciences, Inc.
Date:December 12, 2023By:  /s/ Rachel E. Haurwitz
Rachel E. Haurwitz
President and Chief Executive Officer

 EX-99.1 2 crbu-20231212xexx991.htm EX-99.1 Document
Exhibit 99.1
img25401123_0.jpg

Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024

-- Caribou met with the FDA and reached alignment on a pivotal trial in 2L LBCL with CB-010 versus a comparator arm of immunochemotherapy followed by HDCT and ASCT --

-- ANTLER Phase 1 trial continues dose expansion enrollment; initial dose expansion data and RP2D expected Q2 2024 --

-- Caribou plans to initiate Phase 3 pivotal trial by YE 2024 --

BERKELEY, CA, December 12, 2023 – Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today provided an update based on feedback from the U.S. Food and Drug Administration (FDA) following recent communications and a Type B clinical meeting regarding the CB-010 development program. The company has received the FDA’s feedback on a Phase 3 randomized controlled trial for CB-010, an allogeneic anti-CD19 CAR-T cell therapy in development for patients with second-line relapsed or refractory large B cell lymphoma (r/r LBCL). The FDA stated that Caribou’s proposed comparator arm of platinum-based immunochemotherapy followed by high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) is acceptable.

“FDA feedback on our CB-010 pivotal development plan represents an important step in advancing our lead therapy to enable broader access of CAR-T cell therapies for patients living with large B cell lymphoma,” said Rachel Haurwitz, PhD, Caribou’s president and chief executive officer. “As our ongoing ANTLER trial progresses, we look forward to engaging again with the FDA ahead of initiating our planned Phase 3 pivotal trial. Our goal is to establish a new second-line standard of care by delivering an off-the-shelf CAR-T cell therapy to patients as expeditiously as possible.”

In the ongoing ANTLER Phase 1 trial (https://clinicaltrials.gov/study/NCT04637763), Caribou is enrolling second-line LBCL patients in the dose expansion portion based on promising data (https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-reports-positive-clinical-data-dose) from the dose escalation portion of the trial. Currently, 22 sites are active in the U.S. and the first international site is active in Australia, with additional site activation underway in the U.S. and globally. To Caribou’s knowledge, CB-010 is the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting and it has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations by the FDA. In Q2 2024, the company plans to report initial dose expansion data from the ANTLER trial and share the recommended Phase 2 dose (RP2D) for CB-010. Caribou plans to initiate a Phase 3 pivotal trial with this RP2D by year-end 2024.

About CB-010
CB-010 is the lead product candidate from Caribou’s allogeneic CAR-T cell therapy platform and is being evaluated in patients with relapsed or refractory B cell non-Hodgkin lymphoma (r/r B-NHL). In the ongoing ANTLER Phase 1 trial, Caribou is enrolling second-line patients with large B cell lymphoma (LBCL) comprised of different subtypes of aggressive r/r B-NHL (DLBCL NOS, PMBCL, HGBL, tFL, and tMZL). CB-010 is an allogeneic anti-CD19 CAR-T cell therapy engineered using Cas9 CRISPR
1

img25401123_0.jpg
hybrid RNA-DNA (chRDNA) genome-editing technology. To Caribou’s knowledge, CB-010 is the first allogeneic CAR-T cell therapy in the clinic with a PD-1 knockout, a genome-editing strategy designed to improve antitumor activity by limiting premature CAR-T cell exhaustion. Also, to Caribou’s knowledge, CB-010 is the first anti-CD19 allogeneic CAR-T cell therapy to be evaluated in the second-line LBCL setting and it has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations by the FDA. Additional information on the ANTLER trial (NCT04637763) can be found at clinicaltrials.gov (https://clinicaltrials.gov/study/NCT04637763).

About Caribou’s novel next-generation CRISPR platform
CRISPR genome editing uses easily designed, modular biological tools to make DNA changes in living cells. There are two basic components of Class 2 CRISPR systems: the nuclease protein that cuts DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to an edit at the targeted genomic site. CRISPR systems are capable of editing unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function and phenotype. In response to this challenge, Caribou has developed CRISPR hybrid RNA-DNA guides (chRDNAs; pronounced “chardonnays”) that direct substantially more precise genome editing compared to all-RNA guides. Caribou is deploying the power of its Cas12a chRDNA technology to carry out high efficiency multiple edits, including multiplex gene insertions, to develop CRISPR-edited therapies.

About Caribou Biosciences, Inc.
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve antitumor activity. Caribou is advancing a pipeline of off-the-shelf cell therapies from its CAR-T and CAR-NK platforms as readily available treatments for patients with hematologic malignancies and solid tumors. Follow us @CaribouBio and visit www.cariboubio.com.

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements related to Caribou’s strategy, plans, objectives, and expectations regarding its clinical and preclinical development programs, including its expectations relating to the timing of initiating patient enrollment in the Phase 3 pivotal trial by year-end 2024, reporting of initial dose expansion data from the ongoing ANTLER 1 Phase 1 trial and sharing the recommended Phase 2 dose for CB-010 in Q2 2024, and the timing of updates from its ANTLER Phase 1 clinical trial for CB-010. Management believes that these forward-looking statements are reasonable as and when made. However, such forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include, without limitation, risks inherent in the development of cell therapy products; uncertainties related to the initiation, cost, timing, progress, and results of Caribou’s current and future research and development programs, preclinical studies, and clinical trials; and the risk that initial, preliminary, or interim clinical trial data will not ultimately be predictive of the safety and efficacy of Caribou’s product candidates or that clinical outcomes may differ as patient enrollment continues and as more patient data becomes available; the risk that preclinical study results observed will not be borne out in human patients or different conclusions or considerations are
2

img25401123_0.jpg
reached once additional data have been received and fully evaluated; the ability to obtain key regulatory input and approvals as well as other risk factors described from time to time in Caribou’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2022 and subsequent filings. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Except as required by law, Caribou undertakes no obligation to update publicly any forward-looking statements for any reason.

Caribou Biosciences, Inc. contacts:
Investors:
Amy Figueroa, CFA
investor.relations@cariboubio.com

Media:
Peggy Vorwald, PhD
media@cariboubio.com

###
3
 EX-101.SCH 3 crbu-20231211.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 crbu-20231211_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Document Period End Date Document Period End Date Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Document Type Document Type Entity Central Index Key Entity Central Index Key Amendment Flag Amendment Flag Entity Ex Transition Period Entity Ex Transition Period Entity File Number Entity File Number Entity Address, City or Town Entity Address, City or Town Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Registrant Name Entity Registrant Name EX-101.PRE 5 crbu-20231211_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 img25401123_0.jpg begin 644 img25401123_0.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 11, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date Dec. 11, 2023
Entity Registrant Name Caribou Biosciences, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-40631
Entity Tax Identification Number 45-3728228
Entity Address, Address Line One 2929 7th Street
Entity Address, Address Line Two Suite 105
Entity Address, City or Town Berkeley
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94710
City Area Code 510
Local Phone Number 982-6030
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol CRBU
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Amendment Flag false
Entity Central Index Key 0001619856

XML 8 crbu-20231211_htm.xml IDEA: XBRL DOCUMENT 0001619856 2023-12-11 2023-12-11 false 0001619856 8-K 2023-12-11 Caribou Biosciences, Inc. DE 001-40631 45-3728228 2929 7th Street Suite 105 Berkeley CA 94710 510 982-6030 false false false false Common Stock, $0.0001 par value per share CRBU NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://www.cariboubio.com/role/Cover Cover Cover 1 false false All Reports Book All Reports crbu-20231211.htm crbu-20231211.xsd crbu-20231211_lab.xml crbu-20231211_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "crbu-20231211.htm": { "nsprefix": "crbu", "nsuri": "http://www.cariboubio.com/20231211", "dts": { "inline": { "local": [ "crbu-20231211.htm" ] }, "schema": { "local": [ "crbu-20231211.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "crbu-20231211_lab.xml" ] }, "presentationLink": { "local": [ "crbu-20231211_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://www.cariboubio.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crbu-20231211.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "crbu-20231211.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.cariboubio.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001619856-23-000134-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001619856-23-000134-xbrl.zip M4$L#!!0 ( *J C%?EJ7P; 18 #"% 1 8W)B=2TR,#(S,3(Q,2YH M=&WM/6MWVDB6W^=7U-*[/NEM@_3H[^ MR[+^>'_SD9U%7CH28<(Z2O!$^.Q!)D.6# 7[/5)W\IZSZX G_4B-+(O>ZD3Q M1,G!,&%NU:WEO;)&U6XT1%7T#OH6=P]J5KW':Q:O5EVKYO)>C?N\6FLURH-V MJ][H>XUJS3IH-OM6O>;M6SU_OVZ)5J/5:_#]_9KPRGY[WS\X<*LM9U_X3MWQ M>UQX3K-6]?J]NNZIP([4H"+# M0(8"$:XDBH<:\>$)$*0"2%0M@,]Q2]D@8RWG!GFHT1!NM>I4_OCTL>L-Q8A; M,M0)#SV1O;7J#:?5:E7&"%X^M"^F0Q-L6GCV(+JO0 -"4BM-$;&@;6[4O.]C MN#@-J]JT:DX^#O2\6TT10*=6P>8>UV(Z[;K.3FUFWH)2T"X?&7Z!1NWQ$CAS ME,)6ZMH.>#@X+HG0^MPM 8,%]T^.1B+A#%^UQ+]3>7]1O?_O;42*30)QXJI=:2&''=9RCBGEX5#%#]R)_18P M(.0C'$G(]BGHEX\Z]B'@@Q(S_#HN 8_;?3D6OM7G ?) ^L>EO@5"NEDRK(\K[3:C;VER:IS&.H1%\H M 3S4*QB##&MKT@< @Q$#VPFPX[BDY2@.D/'T;*@(RED>V&/MPQ"5^3',_--) M,QATE"KZ11+7SE GA!#U_+D@O/-?TL???2D4H_'%2FWJ7/PV3X_%ET_R1_.C MQT"NR,]_@9RKY SLYPGB!\;$0BE;;"O ]-=TS5ORW_DDE3F\KZYJKM%&T5&EOE'3(:U>*D1.\!5DB,XQ(8\GG$,U2@)_.C% GS$T![&'/? ME^&@764.C3&=I$*46,4;0YLDB@%GH R1PE#% Q$5JF2XD_<'F"+5QMEPPCZ( M$-B;D0PF[;_?RA'H]:5X8#?1B(=_+VMP)^!WE.R;CEK^*=I.$V:AGP\&W0,8 MAYB5H>^X2+S/EQ>WYV>L>WMZ>]Z=%XH9Z'<%VNYYY_/-Q>W%>9>=7IZQ\S\Z MOYY>_G+..E>?/EUTNQ=7EUM$P=T(A=]/N[]>7/YR>W599F=VQX9XK%%O;1'L MZ@+8]95@_W/#?VL1V54%^'!U\XEM[J3SP-N$+\8W@S%N6K\M^^0?+-V.BH&- MN#F_O&4WY]=7-[>O#OSK5.F40VZ71*PK/,P1F%-CD6).8\]_QZ(^)7K0E"J9 M2)CX?.P-(<03[-1+L-EIU>H[A/:B.*Y&&T,H!/Y&Q)%*V%[^6W (HH1.F+C' MA%=1L_#?M;]":Z\I,CLW\=I\3._#$VL$0PSQ-^9B#/4#$C5[E"#.N63<6'B9*/I,ANT@TZPPAWQ'JW779EV/I3,K1UZ5B><+GQ&%.N9:.S2'5#\&_OR:I?8XK MN$0*O!J5 [L).*).E(:)FG0B?]Y+8741*Q.)B%5TC^-,W5,=W5/ '[@2:RU5 MQH;OCL(?9""@,WCNG%H-+!\Y5KVZ7W-^D&N!7+=\?)%5TCP2RGG:[9=.Z@VK M=N V7;?Y*/&>6ZW!9F_)EY):8@Q^!;&W8O\+H;?V)07G5$\#!SNGQN]>0HBV MAWXG&HVDQK4HAKK$C$"\,20O;KKL?!0'T40H8NJ\$K#+R'ZW2KR?4%=<63E\ MF:Y?KWN!Z"^%,87]VFI$^#RA_ZGO*Z%U]M]'&,_)3=M!Z<1MN2UVD Q9-U%" M)(OVK?R$M'/==&X^7;-TTDTE&!:GVMB=].)ER=Z!/Z_4;?101"ZMTLE[H>Y$ M(";/1FVRUU?J&L(D26N9&T913A4SP$!"]U#RQWGRO,J[^Z%$X^N9?AT!O8/_ ME[$):3-:.Z635OW J;[Y&()(MY?1 I/Q:P52*6,>L/.Q\-)$W@MVU0=/(_13 MG.I+B-?VZ /BP5 ^5CC9'5I7V\PX3JLM/__4=)V#0\UNP<#%PRC,HR>J*@4I M=*L$)]W:.^S9**^S;3+XF_-KY]3 /C==:[]:6V^B7XM"7E9.=[Y@^P%B%$@N+ZEBJUCV,W,;92;[ M6*4-!\)G70QJV$>NDVR]Y+NLVVX#C'>T ,=C"!]C);$PT(O&K">"Z &9 MA(W(.]:T?F-]&:"!EYI)W.KF _.2B&DY2H.$AR)*=3!A&A),W9_0F]D+40]8 M9O+.;,%/30OX*8RC& \G>5L_"F!R? ]#6HF)NFZ_R0JX[;:>OU+=JMN-ZL$+ M5ZI7I=5/"K9^AX%Q> =3[<,+=6M:'CNQ6YYNIZT_X+UIM>M;0_L?;=C0+I 3_"P2.'4.\?N,:LQM M:"D4HPYVF'K^T(UOK1O72J 7P-T0M/L- QEUU>]CLK"9CNQ_/^X B&5Y,]3Z MHE]PZK[E[O7>;:8!IN\/'=BR#EQHG0KU%9IP\$,3UFM"35CU/6\S3OKWO;I:4/:VM7MU_]@S2 M=>UJ\VL!^M; F4/FD\Z.O/Z%Z\0W5L\/VCV%'M#Y@596 M<41EA\J*JWG:G8QZ4;"G5WF![VAMEDK<9N# M$8M)#1J6^3TS;A5LSVGW[/3_V"]!! D/Q*D!1*KL$U=WRSNHOGYU?TLUK(O0 MQXQ%L-Z$>;3\ W#=@545M!=T86U&:@8@0KJ#H _80$4/R1 3GQC7:[AFONC# M%'3PPE2%JXT59[JF1[EJ;._GGYS]@T/<25!K'5*!.'\'9@-FQ7AR Y<,31+E M]BQWPV-BBV-C7C5]?69T>\?7Y<[7$/R)2_#??(W%;)/*H?^%@.\8V#7?0?494R*,A*O9-+RZ%#T"JR.*!58429.F* MI.S9W,^ Q*6Y@@E.3A?HH,"$@!NT*'$O-;P'NLI##\O6W//P6 9VQ@M2?*Y\ M;99;_75I>FV/%VGZK/;9KT4LQ[<%VL-E2I>UUT4LW>$Q)'A M;EN)@.,VQ*5;0Z9@T/S5Z2N\!Q%1FBR_\J6+1IY\VTFUE+\T5-,X;B"LGA+\ MSN)]\%!M'CSPB2Y5GOM.E%7RV?P&-G-UD? B$2/6L*LN.Q.0>B2IHISO3"HP M.I'2:+LZ(.HW,CD!JWTC_[R79?;)/K/+9*4[0RGZ[)- SQ/D MJ!!VZXX%LSU\#^,GMWJ8>6[ZY1R^*X-;"0+6$RP0_!X]!\V1A2:BWT>&W M6 MG"NO9>?*;39["\"9L@VDQ5[2'#!S7(6X=CI0PA39B[O@\HGV DS\?0P^S\=# MV9,).8'=S,Y5=S.%*ELEY)& N$1>68<["(. M+F!? )[3 ?PM^.20+O*BC5!>)C0QGQA! L<*_4*(D1/<,H4^*LS$EO#"F!2T M'?2ZV!PEID1 CP9DQC_3&%H15'CF2[/>H$6"&, PTK0]1D<,0/+]N<+LTH81 M$;Z"<6&VG9O#R*",!B(^SP@PK()K4E(OX')$6/7Y?:3RR" CO\U.81BNO"'F M$&8!!"P:D9Q36+)2.%>HV696M3FUJKMIY0[LJH/'UM/ $/;#&9@M[061!J.W MX];E*IPJA.,:I2[/*:7$]4/020@A48IR,>%A"%&F9VP%AW02PUL?FCT! @?Q MJ!# 2XB%^RH:T8"?[:X-&@H1+"(@ MP@0#)JW.F=-BG=,;ZQ;4'

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end